FORM 10-K: 2003
EXHIBIT 10.65
AMENDMENT NO.1 TO EXCLUSIVITY TRANSFER AGREEMENT
This Amendment No.1 is made as of December 30, 2003 to the Exclusivity
Transfer Agreement dated as of July 31, 2003 by and among ANDRX PHARMACEUTICALS,
LLC, a Delaware limited liability company, ANDRX PHARMACEUTICALS, INC., a
Florida corporation, IMPAX LABORATORIES, INC., a Delaware corporation, and TEVA
PHARMACEUTICALS CURACAO N.V., a Netherlands Antilles company.
WITNESSETH:
NOW, THEREFORE; the Parties hereto hereby agree as follows:
1. Amendment. Effective as of the date of the Agreement, the Agreement
is hereby amended to amend and restate Section 6.2 in its entirety as follows:
"Section 6.2. Special Provisions Following and Prior to Viability Date.
(a) In addition, any information exchanged by the Parties following
delivery of a Viability Date Notice given pursuant to Section 2.5(e) and (f)
shall be provided only to (1)(a) the outside advisors (e.g. financial advisors,
lawyers or accountants) of the receiving Party and (b) officers of the receiving
Party specifically approved by the disclosing Party (not including sales and
marketing personnel), if any, which approval shall not be unreasonably withheld,
and in each case of clauses (a) and (b), who need to review such information in
connection with the determination of the Alternative Payment, and (2) the
arbitrators designated pursuant to Section 2.5(e). Such information shall be
used by such persons solely in connection with the determination of the
Alternative Payment.
(b) In addition, any information exchanged by the Parties prior to
delivery of a Viability Date Notice given pursuant to Section 2.5(e) and (f)
shall be disclosed only to persons at the receiving Party who need to know the
information for purposes of determining compliance with this Agreement, who
shall use such information for that purpose only, and who shall not include any
person whose principal and specific responsibility is for sales or marketing."
2. Definitions; References. Capitalized terms used in this Amendment
but not defined herein shall have the meanings ascribed to them in the
Agreement.
3. Full Force and Effect. Except as expressly modified hereby, all
provisions of the Agreement shall remain in full force and effect.
4. Counterparts. This Amendment may be executed in counterparts, each
of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.
IN WITNESS WHEREOF, the parties have executed this Amendment to the
Agreement as of the date first written above.
ANDRX PHARMACEUTICALS, LLC
By: /s/ Xxxxx Xxxxx
--------------------------------------
Name: Xxxxx Xxxxx
Title: E.V.P. & General Counsel
ANDRX PHARMACEUTICALS, INC.
By: /s/ Xxxxx Xxxxx
--------------------------------------
Name: Xxxxx Xxxxx
Title: E.V.P. & General Counsel
IMPAX LABORATORIES, INC.
By: /s/ Xxxxx X. Xxxxxxx
--------------------------------------
Name: Xxxxx X. Xxxxxxx
Title: Co-CEO
TEVA PHARMACEUTICALS CURACAO N.V.
By: /s/ Xxx Xxxxxxxxx
--------------------------------------
Name: Xxx Xxxxxxxxx
Title: Managing Director
By: /s/ MeesPierson Trust (Curacao) N.V.
--------------------------------------
Name: MeesPierson Trust (Curacao) N.V.
Title: Managing Director
- 2 -
